DARVON COMPOUND-65 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Darvon Compound-65, and when can generic versions of Darvon Compound-65 launch?
Darvon Compound-65 is a drug marketed by Xanodyne Pharm and is included in one NDA.
The generic ingredient in DARVON COMPOUND-65 is aspirin; caffeine; propoxyphene hydrochloride. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; caffeine; propoxyphene hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for DARVON COMPOUND-65?
- What are the global sales for DARVON COMPOUND-65?
- What is Average Wholesale Price for DARVON COMPOUND-65?
Summary for DARVON COMPOUND-65
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 124 |
DailyMed Link: | DARVON COMPOUND-65 at DailyMed |
US Patents and Regulatory Information for DARVON COMPOUND-65
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Xanodyne Pharm | DARVON COMPOUND-65 | aspirin; caffeine; propoxyphene hydrochloride | CAPSULE;ORAL | 010996-007 | Mar 8, 1983 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |